Last reviewed · How we verify
NCT06084468
Cardiac Structure and Function in Patients with Cystic Fibrosis
trial in Cystic Fibrosis in 104 participants. Participants enrolled and being followed up; not accepting new ones.
1 March 2023
Quick facts
| Lead sponsor | Herlev and Gentofte Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 104 |
| Start date | 1 January 2023 |
| Primary completion | 1 March 2023 |
| Estimated completion | 1 March 2032 |
| Sites | 2 locations across Denmark |
Conditions studied
- Cystic Fibrosis — all drugs for Cystic Fibrosis →
- Cystic Fibrosis-related Diabetes — all drugs for Cystic Fibrosis-related Diabetes →
- Cystic Fibrosis, Pulmonary — all drugs for Cystic Fibrosis, Pulmonary →
- Cystic Fibrosis of Pancreas — all drugs for Cystic Fibrosis of Pancreas →
Sponsor
Herlev and Gentofte Hospital
Who can join
18 and older, any sex, with Cystic Fibrosis or Cystic Fibrosis-related Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In a prospective observational cohort study (n = 100), the investigators aim to assess the correlation between cardiac biomarkers, advanced echocardiography and cystic fibrosis genotype and severity and determine whether these are prognostic markers of heart disease in patients suffering from cystic fibrosis (CF).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06084468
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cystic Fibrosis
Currently open trials in the same condition.
- NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
- NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
- NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
- NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
- NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting
Other Herlev and Gentofte Hospital trials
Trials by the same sponsor.
- NCT07493590 — CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction · not yet recruiting
- NCT07321964 — The Effect of a Digital MediYoga Program on Quality of Life, Blood Pressure and Heart Rate Among Patients With Atrial Fi · NA · recruiting
- NCT06706661 — Implementation of Nutritional Efforts on Discharged Older Patients · NA · recruiting
- NCT06618417 — Evaluating the Impact of Home-Based Sleep Apnea Diagnostic on Well-Being, Health Behavior, and AF Load in Patients with · NA · recruiting
- NCT06642272 — A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Hea · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06084468 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Herlev and Gentofte Hospital
- Last refreshed: 13 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06084468.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing